FDA approves Revlimid for myeloma maintenance after stem cell transplant – Healio
Oncology Nursing News |
FDA approves Revlimid for myeloma maintenance after stem cell transplant
Healio Lenalidomide (Revlimid, Celgene) is the only FDA–approved treatment for maintenance after autologous HSCT. “Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple myeloma patients … FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma …Yahoo Finance Maintenance Revlimid Gains FDA Approval for Multiple MyelomaCuretoday.com FDA Approves Maintenance Lenalidomide for MyelomaOncLive |
Oncology Nursing News |
FDA approves Revlimid for myeloma maintenance after stem cell transplant
Healio Lenalidomide (Revlimid, Celgene) is the only FDA–approved treatment for maintenance after autologous HSCT. “Autologous stem cell transplant after induction therapy is part of the continuum of care for transplant-eligible multiple myeloma patients … FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma …Yahoo Finance Maintenance Revlimid Gains FDA Approval for Multiple MyelomaCuretoday.com FDA Approves Maintenance Lenalidomide for MyelomaOncLive |
Biomass Magazine |
The RFS in 2017: A Brave New World
Biomass Magazine The industry—and particularly the advanced industry—cannot stand to be left in suspended animation for more time if we are going to support the RFS program’s growth. Third, moving the point of obligation is a Trojan horse. Doing so would lead to the … |
|
Researchers take broad look at stem cells
Science Daily “Continued research into the application of SVF and adipose derived stem cells has the potential to transform treatments and therapy options,” said Daniel Kota, assistant research scientist for Sanford Research. “But it all starts with putting … |
CBS Local |
Angels’ Garrett Richards Among Pitchers Using Stem Cell Treatment Over Tommy John Surgery
CBS Local This, combined with new advances in stem cell technology, gave Richards the option to avoid going under the knife and instead undergo stem cell treatment. This and much more on the topic of stem cell research and its role in baseball was revealed in a … |
OncLive |
Dendritic Immunotherapy Falters in Phase III RCC Trial
OncLive An Independent Data Monitoring Committee (IDMC) has recommended halting the phase III ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC), following a futility analysis. Despite this … Argos Therapeutics (ARGS) Says IDMC Recommends Discontinuation of ADAPT Phase 3 Trial of Rocapuldencel-T in …StreetInsider.com Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of …GlobeNewswire (press release) Argos kidney cancer vax fails interim phase 3 futility reviewFierceBiotech Genetic Engineering & Biotechnology News –Seeking Alpha all 31 news articles » |
BBC News |
Six-year-old boy’s stem cell campaign ‘potentially saves 14 lives’
BBC News Fourteen people have been given potentially life-saving stem cell donations thanks to a campaign launched to help a young boy with leukaemia. A match was found for Joel Picker-Spence, but it was too late and he died shortly before his seventh birthday … |